Lustgarten Foundation

Cancer’s SOS

Stephen Fesik and colleagues are advancing cancer drug discovery with the characterization of small molecules that modulate RAS, an important target for anti-cancer therapies.

Grant bolsters pancreatic cancer drug discovery efforts

The Lustgarten Foundation has awarded a $1.5 million Research Investigator Grant to Stephen Fesik, Ph.D., professor of Biochemistry, Pharmacology and Chemistry, for research designed to discover new drugs for the treatment of pancreatic cancer.

A new way to target cancer-driver Ras

Vanderbilt researchers have discovered small molecules that turn off cancerous Ras signals in a new way.